Sugi Predict

Sugi Predict / Targets / PDCD1LG2

PDCD1LG2

Programmed cell death 1 ligand 2 · Q9BQ51 · PDCD1LG2 on Sugi Atlas →

24,843 patent compounds predicted against PDCD1LG2, 14,049 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1776816 SCHEMBL1776816 0.53 10/20
SCHEMBL9533834 SCHEMBL9533834 0.43 10/20
SCHEMBL5792395 SCHEMBL5792395 0.43 9/20
SCHEMBL6826510 SCHEMBL6826510 0.41 8/20
SCHEMBL7735649 SCHEMBL7735649 0.38 8/20
SCHEMBL5010358 SCHEMBL5010358 0.51 7/20
SCHEMBL8275768 SCHEMBL8275768 0.41 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL7736132) 0.39 7/20
SCHEMBL8275767 SCHEMBL8275767 0.36 7/20
SCHEMBL8275853 SCHEMBL8275853 0.49 6/20
SCHEMBL12362313 SCHEMBL12362313 0.46 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL7735623) 0.41 6/20
SCHEMBL426830 SCHEMBL426830 0.41 6/20
SCHEMBL8275766 SCHEMBL8275766 0.40 6/20
SCHEMBL4361070 SCHEMBL4361070 0.40 6/20
SCHEMBL6823641 SCHEMBL6823641 0.40 6/20
SCHEMBL2673574 SCHEMBL2673574 0.40 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL7727710) 0.39 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL7735647) 0.38 6/20
SCHEMBL4005455 SCHEMBL4005455 0.37 6/20

Clinical trials — most relevant to PDCD1LG2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria PHASE4RECRUITING
Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain PHASE2/PHASE3UNKNOWN
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma PHASE3COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer PHASE2RECRUITING
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer PHASE2COMPLETED
TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer PHASE2UNKNOWN
Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer PHASE2UNKNOWN
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors PHASE2COMPLETED
PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer PHASE2ACTIVE_NOT_RECRUITING
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer PHASE2ACTIVE_NOT_RECRUITING
MPDL3280A-treatment-IST-UMCG PHASE2UNKNOWN
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype PHASE2ACTIVE_NOT_RECRUITING
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) PHASE2COMPLETED
Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer PHASE1/PHASE2COMPLETED
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary PHASE2UNKNOWN
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide PHASE2COMPLETED
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) PHASE2COMPLETED
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma PHASE2UNKNOWN
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) PHASE2COMPLETED
Pembrolizumab in High-risk Thyroid Cancer PHASE2RECRUITING
Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) PHASE1COMPLETED
Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer nanUNKNOWN
Role of Programmed Death Ligand 1 in Colorectal Cancer nanNOT_YET_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Immune Checkpoints in Intraabdominal Ascites Fluid nanCOMPLETED
WGA in Platinum-refractory HNSCC Underwent Nivolumab nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PDCD1LG2 binder may also engage these)

ProteinNameSimilarity
Q9WUL5 — 0.982 Q9WUL5 →
ICOSLG ICOS ligand 0.980 landscape →
P33681 — 0.974 P33681 →
P20917 — 0.969 P20917 →
Q28110 — 0.966 Q28110 →
P15151 — 0.966 P15151 →
P32506 — 0.965 P32506 →
MAG Myelin-associated glycoprotein 0.965 landscape →
P54900 — 0.964 P54900 →
Q6AYP5 — 0.963 Q6AYP5 →
P07722 — 0.962 P07722 →
Q56A07 — 0.961 Q56A07 →
Q15223 — 0.959 Q15223 →
P38484 — 0.959 P38484 →
P27930 — 0.958 P27930 →
P04216 — 0.958 P04216 →
Q9JKF6 — 0.958 Q9JKF6 →
P31994 — 0.958 P31994 →
Q9NPH3 — 0.957 Q9NPH3 →
P42070 — 0.957 P42070 →
Q9GL76 — 0.957 Q9GL76 →
A8MVS5 — 0.957 A8MVS5 →
Q61730 — 0.957 Q61730 →
Q3TEW6 — 0.957 Q3TEW6 →
O62643 — 0.956 O62643 →
P01831 — 0.956 P01831 →
P31995 — 0.956 P31995 →
O18796 — 0.956 O18796 →
P30433 — 0.955 P30433 →
Q63621 — 0.955 Q63621 →